Zhuhai Federal Biomedical Co., Ltd.

To study the efficacy and safety of degludec insulin liraglutide injection developed by United Biotechnology in patients with type 2 diabetes.

The primary objective is to investigate the pharmacokinetic characteristics of degludec insulin liraglutide injection and to compare the pharmacokinetic similarity of a single subcutaneous injection of degludec insulin liraglutide (test preparation) with the original drug "NovoElix®" (reference preparation) in healthy Chinese adult subjects. The secondary objective is to evaluate the safety of degludec insulin liraglutide injection and preliminarily evaluate its immunogenicity.

This study used semaglutide injection developed by United Biotech (Zhuhai Hengqin) Co., Ltd. and semaglutide injection (trade name: Novo Nordisk®) to treat patients with type 2 diabetes for 32 weeks, and compared the decrease and target rate of glycated hemoglobin and fasting blood glucose before and after treatment, as well as changes in body weight; at the same time, the incidence of hypoglycemia, gastrointestinal events and other related safety indicators and immunogenicity indicators were compared between the two groups, as well as the similarity of pharmacokinetics between the two groups. The main purpose is to evaluate the similarity of the effectiveness and safety of semaglutide injection developed by United Biotech and Novo Nordisk® in patients with type 2 diabetes.